Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Patients With Prurigo Nodularis

NCT06366750 is registered in ClinicalTrials.gov with Celldex Therapeutics as lead sponsor.

NCT NCT06366750
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06366750 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Patients With Prurigo Nodularis
Lead sponsor
Celldex Therapeutics
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 12, 2024
Completion date
March 31, 2027
Enrollment
140 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

prurigo nodularis